GLP-1 drugs, originally developed for diabetes and obesity, may also curb addictive behaviors by acting on reward circuits in the brain. Early trials show reductions in alcohol intake, opioid seeking, and nicotine use. Though more research is needed, scientists believe these drugs could open a powerful new front in addiction therapy.
Source: https://www.sciencedaily.com/releases/2 ... 021746.htm
Source: https://www.sciencedaily.com/releases/2 ... 021746.htm
